サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1139938

インターベンショナルオンコロジー市場：製品別 - 世界の機会分析および産業予測、2021-2031年

Interventional Oncology Market By Product : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 176 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
インターベンショナルオンコロジー市場：製品別 - 世界の機会分析および産業予測、2021-2031年
出版日: 2022年07月01日
発行: Allied Market Research
ページ情報: 英文 176 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

インターベンショナルオンコロジーの世界市場規模は、2021年の21億3130万米ドルから急増し、2030年には37億9150万米ドルに達し、注目すべきCAGR6.5％で推移すると予測されています。

インターベンショナルオンコロジー（IO）は、がん治療を改善するために画像誘導による処置（診断／手術）を行うことに焦点を当てた新しい専門分野です。外科手術、薬物療法、放射線療法と並んで、IOは現在、現代の腫瘍治療の4本目の柱となっています。世界中の人々の間でがん患者が増加していることから、インターベンショナルオンコロジー市場は予測期間中に拡大を加速させると予想されています。がんは、世界で最も急速に増加している健康問題の一つであり、乳幼児から高齢者まで、あらゆる年齢の人々に影響を与えています。乳がんや咽頭がんは、人々に最も多く見られるがんの一種です。このように、がん患者数の増加に伴い、がん治療に対する技術的なニーズも高まっています。このことは、今後数年間における市場の積極的な拡大に寄与すると予測されます。しかし、インターベンショナルオンコロジー療法は比較的新しい治療法であるため、市場への浸透度は低く、認知度も低いです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析
  • バリューチェーン分析
  • 主要規制の分析
  • 市場シェア分析
  • 規制ガイドライン

第4章 インターベンショナルオンコロジー市場：製品タイプ別

  • 概要
    • 市場規模・予測
  • 塞栓用デバイス
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • アブレーションデバイス
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • サポートデバイス
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第5章 インターベンショナルオンコロジー市場：がん種別

  • 概要
    • 市場規模および予測
  • 肝臓がん
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 肺がん
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 乳がん
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 前立腺癌
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 腎臓癌
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 骨転移
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • その他の癌
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第6章 インターベンショナルオンコロジー市場：エンドユーザー別

  • 概要
    • 市場規模・予測
  • 病院
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 外来手術センター
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 研究・学術機関
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第7章 インターベンショナルオンコロジー市場：地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米市場規模・予測：製品タイプ別
    • 北米市場規模・予測：がんタイプ別
    • 北米市場規模・予測：エンドユーザー別
    • 北米市場規模・予測：国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州市場規模・予測：製品タイプ別
    • 欧州市場規模・予測：がんタイプ別
    • 欧州市場規模・予測：エンドユーザー別
    • 欧州市場規模・予測：国別
      • ドイツ
      • 英国
      • フランス
      • スペイン
      • イタリア
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測：製品タイプ別
    • アジア太平洋地域の市場規模・予測：がんタイプ別
    • アジア太平洋地域の市場規模・予測：エンドユーザー別
    • アジア太平洋地域の市場規模・予測：国別
      • 中国
      • 日本
      • インド
      • 韓国
      • オーストラリア
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測：製品タイプ別
    • LAMEAの市場規模・予測：がんタイプ別
    • LAMEAの市場規模・予測：エンドユーザー別
    • LAMEAの市場規模・予測：国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • Medtronic, Inc.
  • Boston Scientific Corporation
  • BD
  • Terumo Corporation
  • Merit Medical
  • AngioDynamics
  • Johnson & Johnson
  • Teleflex Incorporated
  • Cook Group
  • HealthTronics, Inc.
図表

LIST OF TABLES

  • TABLE 1. GLOBAL INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT TYPE, 2021-2030,($MILLION)
  • TABLE 2. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR EMBOLIZATION DEVICES, BY REGION , 2021-2030,($MILLION)
  • TABLE 3. INTERVENTIONAL ONCOLOGY MARKET EMBOLIZATION DEVICES BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 4. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR ABLATION DEVICES, BY REGION , 2021-2030,($MILLION)
  • TABLE 5. INTERVENTIONAL ONCOLOGY MARKET ABLATION DEVICES BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 6. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR SUPPORT DEVICES, BY REGION , 2021-2030,($MILLION)
  • TABLE 7. INTERVENTIONAL ONCOLOGY MARKET SUPPORT DEVICES BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 8. GLOBAL INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2021-2030,($MILLION)
  • TABLE 9. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR LIVER CANCER, BY REGION , 2021-2030,($MILLION)
  • TABLE 10. INTERVENTIONAL ONCOLOGY MARKET LIVER CANCER BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 11. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR LUNG CANCER, BY REGION , 2021-2030,($MILLION)
  • TABLE 12. INTERVENTIONAL ONCOLOGY MARKET LUNG CANCER BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 13. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR BREAST CANCER, BY REGION , 2021-2030,($MILLION)
  • TABLE 14. INTERVENTIONAL ONCOLOGY MARKET BREAST CANCER BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 15. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR PROSTATE CANCER, BY REGION , 2021-2030,($MILLION)
  • TABLE 16. INTERVENTIONAL ONCOLOGY MARKET PROSTATE CANCER BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 17. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR KIDNEY CANCER, BY REGION , 2021-2030,($MILLION)
  • TABLE 18. INTERVENTIONAL ONCOLOGY MARKET KIDNEY CANCER BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 19. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR BONE METASTASIS, BY REGION , 2021-2030,($MILLION)
  • TABLE 20. INTERVENTIONAL ONCOLOGY MARKET BONE METASTASIS BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 21. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR OTHER CANCERS, BY REGION , 2021-2030,($MILLION)
  • TABLE 22. INTERVENTIONAL ONCOLOGY MARKET OTHER CANCERS BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 23. GLOBAL INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2021-2030,($MILLION)
  • TABLE 24. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR HOSPITALS, BY REGION , 2021-2030,($MILLION)
  • TABLE 25. INTERVENTIONAL ONCOLOGY MARKET HOSPITALS BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 26. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR AMBULATORY SURGERY CENTERS, BY REGION , 2021-2030,($MILLION)
  • TABLE 27. INTERVENTIONAL ONCOLOGY MARKET AMBULATORY SURGERY CENTERS BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 28. INTERVENTIONAL ONCOLOGY MARKET REVENUE, FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION , 2021-2030,($MILLION)
  • TABLE 29. INTERVENTIONAL ONCOLOGY MARKET RESEARCH AND ACADEMIC INSTITUTES BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 30. INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2021-2030,($MILLION)
  • TABLE 31. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT TYPE, 2021-2030,($MILLION)
  • TABLE 32. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2021-2030,($MILLION)
  • TABLE 33. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2021-2030,($MILLION)
  • TABLE 34. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 35. U.S. INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 36. U.S. INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 37. U.S. INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 38. CANADA INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 39. CANADA INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 40. CANADA INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 41. MEXICO INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 42. MEXICO INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 43. MEXICO INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 44. EUROPE INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT TYPE, 2021-2030,($MILLION)
  • TABLE 45. EUROPE INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2021-2030,($MILLION)
  • TABLE 46. EUROPE INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2021-2030,($MILLION)
  • TABLE 47. EUROPE INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 48. GERMANY INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 49. GERMANY INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 50. GERMANY INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 51. U.K. INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 52. U.K. INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 53. U.K. INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 54. FRANCE INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 55. FRANCE INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 56. FRANCE INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 57. SPAIN INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 58. SPAIN INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 59. SPAIN INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 60. ITALY INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 61. ITALY INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 62. ITALY INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 63. REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 64. REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 65. REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 66. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT TYPE, 2021-2030,($MILLION)
  • TABLE 67. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2021-2030,($MILLION)
  • TABLE 68. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2021-2030,($MILLION)
  • TABLE 69. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 70. CHINA INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 71. CHINA INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 72. CHINA INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 73. JAPAN INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 74. JAPAN INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 75. JAPAN INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 76. INDIA INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 77. INDIA INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 78. INDIA INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 79. SOUTH KOREA INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 80. SOUTH KOREA INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 81. SOUTH KOREA INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 82. AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 83. AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 84. AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 86. REST OF ASIA PACIFIC INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 87. REST OF ASIA PACIFIC INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 88. LAMEA INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT TYPE, 2021-2030,($MILLION)
  • TABLE 89. LAMEA INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2021-2030,($MILLION)
  • TABLE 90. LAMEA INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2021-2030,($MILLION)
  • TABLE 91. LAMEA INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2021-2030,($MILLION)
  • TABLE 92. BRAZIL INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 93. BRAZIL INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 94. BRAZIL INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 95. SAUDI ARABIA INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 96. SAUDI ARABIA INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 97. SAUDI ARABIA INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 98. SOUTH AFRICA INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 99. SOUTH AFRICA INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 100. SOUTH AFRICA INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 101. REST OF LAMEA INTERVENTIONAL ONCOLOGY MARKET BY PRODUCT TYPE 2021-2030,($MILLION)
  • TABLE 102. REST OF LAMEA INTERVENTIONAL ONCOLOGY MARKET BY CANCER TYPE 2021-2030,($MILLION)
  • TABLE 103. REST OF LAMEA INTERVENTIONAL ONCOLOGY MARKET BY END USER 2021-2030,($MILLION)
  • TABLE 104.MEDTRONIC, INC.: COMPANY SNAPSHOT
  • TABLE 105.MEDTRONIC, INC.: OPERATING SEGMENTS
  • TABLE 106.MEDTRONIC, INC.: PRODUCT PORTFOLIO
  • TABLE 107.MEDTRONIC, INC.: NET SALES,
  • TABLE 108.MEDTRONIC, INC.: KEY STRATERGIES
  • TABLE 109.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 110.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 111.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 112.BOSTON SCIENTIFIC CORPORATION: NET SALES,
  • TABLE 113.BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
  • TABLE 114.BD: COMPANY SNAPSHOT
  • TABLE 115.BD: OPERATING SEGMENTS
  • TABLE 116.BD: PRODUCT PORTFOLIO
  • TABLE 117.BD: NET SALES,
  • TABLE 118.BD: KEY STRATERGIES
  • TABLE 119.TERUMO CORPORATION: COMPANY SNAPSHOT
  • TABLE 120.TERUMO CORPORATION: OPERATING SEGMENTS
  • TABLE 121.TERUMO CORPORATION: PRODUCT PORTFOLIO
  • TABLE 122.TERUMO CORPORATION: NET SALES,
  • TABLE 123.TERUMO CORPORATION: KEY STRATERGIES
  • TABLE 124.MERIT MEDICAL: COMPANY SNAPSHOT
  • TABLE 125.MERIT MEDICAL: OPERATING SEGMENTS
  • TABLE 126.MERIT MEDICAL: PRODUCT PORTFOLIO
  • TABLE 127.MERIT MEDICAL: NET SALES,
  • TABLE 128.MERIT MEDICAL: KEY STRATERGIES
  • TABLE 129.ANGIODYNAMICS: COMPANY SNAPSHOT
  • TABLE 130.ANGIODYNAMICS: OPERATING SEGMENTS
  • TABLE 131.ANGIODYNAMICS: PRODUCT PORTFOLIO
  • TABLE 132.ANGIODYNAMICS: NET SALES,
  • TABLE 133.ANGIODYNAMICS: KEY STRATERGIES
  • TABLE 134.JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 135.JOHNSON & JOHNSON: OPERATING SEGMENTS
  • TABLE 136.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 137.JOHNSON & JOHNSON: NET SALES,
  • TABLE 138.JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 139.TELEFLEX INCORPORATED: COMPANY SNAPSHOT
  • TABLE 140.TELEFLEX INCORPORATED: OPERATING SEGMENTS
  • TABLE 141.TELEFLEX INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 142.TELEFLEX INCORPORATED: NET SALES,
  • TABLE 143.TELEFLEX INCORPORATED: KEY STRATERGIES
  • TABLE 144.COOK GROUP: COMPANY SNAPSHOT
  • TABLE 145.COOK GROUP: OPERATING SEGMENTS
  • TABLE 146.COOK GROUP: PRODUCT PORTFOLIO
  • TABLE 147.COOK GROUP: NET SALES,
  • TABLE 148.COOK GROUP: KEY STRATERGIES
  • TABLE 149.HEALTHTRONICS, INC.: COMPANY SNAPSHOT
  • TABLE 150.HEALTHTRONICS, INC.: OPERATING SEGMENTS
  • TABLE 151.HEALTHTRONICS, INC.: PRODUCT PORTFOLIO
  • TABLE 152.HEALTHTRONICS, INC.: NET SALES,
  • TABLE 153.HEALTHTRONICS, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.INTERVENTIONAL ONCOLOGY MARKET SEGMENTATION
  • FIGURE 2.INTERVENTIONAL ONCOLOGY MARKET,2021-2030
  • FIGURE 3.INTERVENTIONAL ONCOLOGY MARKET,2021-2030
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.INTERVENTIONAL ONCOLOGY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.VALUE CHAIN ANALYSIS
  • FIGURE 13.KEY REGULATION ANALYSIS
  • FIGURE 14.MARKET SHARE ANALYSIS
  • FIGURE 15.REGULATORY GUIDELINES
  • FIGURE 16.INTERVENTIONAL ONCOLOGY MARKET,BY PRODUCT TYPE,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF EMBOLIZATION DEVICES INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ABLATION DEVICES INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SUPPORT DEVICES INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 20.INTERVENTIONAL ONCOLOGY MARKET,BY CANCER TYPE,2021(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF LIVER CANCER INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF LUNG CANCER INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF BREAST CANCER INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF PROSTATE CANCER INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF KIDNEY CANCER INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF BONE METASTASIS INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OTHER CANCERS INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 28.INTERVENTIONAL ONCOLOGY MARKET,BY END USER,2021(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF HOSPITALS INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF AMBULATORY SURGERY CENTERS INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 31.COMPARATIVE SHARE ANALYSIS OF RESEARCH AND ACADEMIC INSTITUTES INTERVENTIONAL ONCOLOGY MARKET,2021-2030(%)
  • FIGURE 32.INTERVENTIONAL ONCOLOGY MARKET BY REGION,2021
  • FIGURE 33.U.S. INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 34.CANADA INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 35.MEXICO INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 36.GERMANY INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 37.U.K. INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 38.FRANCE INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 39.SPAIN INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 40.ITALY INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 41.REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 42.CHINA INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 43.JAPAN INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 44.INDIA INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 45.SOUTH KOREA INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 46.AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 47.REST OF ASIA PACIFIC INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 48.BRAZIL INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 49.SAUDI ARABIA INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 50.SOUTH AFRICA INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 51.REST OF LAMEA INTERVENTIONAL ONCOLOGY MARKET,2021-2030($MILLION)
  • FIGURE 52. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 53. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 54. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 55.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 56.COMPETITIVE DASHBOARD
  • FIGURE 57.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 58.MEDTRONIC, INC..: NET SALES ,($MILLION)
  • FIGURE 59.BOSTON SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 60.BD.: NET SALES ,($MILLION)
  • FIGURE 61.TERUMO CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 62.MERIT MEDICAL.: NET SALES ,($MILLION)
  • FIGURE 63.ANGIODYNAMICS.: NET SALES ,($MILLION)
  • FIGURE 64.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
  • FIGURE 65.TELEFLEX INCORPORATED.: NET SALES ,($MILLION)
  • FIGURE 66.COOK GROUP.: NET SALES ,($MILLION)
  • FIGURE 67.HEALTHTRONICS, INC..: NET SALES ,($MILLION)
目次
Product Code: A03361

The global interventional oncology market size is expected to reach up to $3,791.50 million by 2030, surging from $2,131.30 million in 2021, at a noteworthy CAGR of 6.5%.

Interventional oncology (IO) is an emerging specialty that focuses on using image-guided procedures (diagnostics/surgeries) to improve cancer therapy. Along with surgery, medication, and radiation, IO is currently the fourth pillar of modern oncology care. Due to an increase in cancer cases among people worldwide, the interventional oncology market is expected to accelerate its expansion over the forecast period. Cancer is one of the fastest rising health problems in the world, impacting people of all ages, from infants to the elderly. Breast cancer and throat cancer are two of the most common types of cancer in people. The need for technologically improved cancer management therapy has expanded in tandem with the rise in the number of cancer patients. This aspect is predicted to contribute to the market's positive expansion in the following years. However, because interventional oncology therapy is a relatively new branch of treatment, its market penetration is low, and few people are aware of it.

The global interventional oncology market is segmented on the basis of product type, cancer type, and end user. On basis of product type, the market has been divided into embolization devices, ablation devices, and support devices.  Based on cancer type, the market has been divided into liver cancer, lung cancer, bone metastasis, kidney cancer, breast cancer, prostate cancer, and other cancers. Based on end-user, the market has been categorized into hospitals, ambulatory surgery centers, and research & academic institutes. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the leading interventional oncology market players are Medtronic, Boston Scientific, BD, Terumo, Merit Medical, AngioDynamics, J&J, Teleflex, Cook Medical, and HealthTronics.

KEY MARKET SEGMENTS

By Product Type

  • Embolization Devices
  • Ablation Devices
  • Support Devices

By Cancer Type

  • Liver Cancer
  • Lung Cancer
  • Bone Metastasis
  • Kidney Cancer
  • Breast Cancer
  • Prostate Cancer
  • Other Cancers

By End User

  • Hospitals
  • Ambulatory Surgery Centers
  • Research & Academic Institutes

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • Saudi Arab Emirate
  • South Africa
  • Rest of LAMEA
  • Key Players
  • Medtronic
  • Boston Scientific
  • BD
  • Terumo
  • Merit Medical
  • AngioDynamics
  • J&J
  • Teleflex
  • Cook Medical
  • HealthTronics.
  • Key Market Segments

By Product

  • Ablation
    • Radiofrequency Ablation Devices
    • Microwave Ablation Devices
    • Cryoablation Devices
    • Others
  • Particle Embolization
    • Radioembolic agents
    • Drug-Eluting Beads
    • Others
  • Support Devices

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Alpinion Medical Systems Co. Ltd.
    • AngioDynamics
    • Boston Scientific Corporation
    • Hologic, Inc.
    • Medtronic Plc.
    • Merit Medical
    • Profound Medical
    • Siemens Healthineers
    • Teleflex Incorporated
    • Terumo Corporation

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Value Chain Analysis
  • 3.8.Key Regulation Analysis
  • 3.9.Market Share Analysis
  • 3.10.Regulatory Guidelines

CHAPTER 4: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Embolization Devices
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Ablation Devices
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Support Devices
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Liver Cancer
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Lung Cancer
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Breast Cancer
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Prostate Cancer
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country
  • 5.6 Kidney Cancer
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market analysis by country
  • 5.7 Bone Metastasis
    • 5.7.1 Key market trends, growth factors and opportunities
    • 5.7.2 Market size and forecast, by region
    • 5.7.3 Market analysis by country
  • 5.8 Other Cancers
    • 5.8.1 Key market trends, growth factors and opportunities
    • 5.8.2 Market size and forecast, by region
    • 5.8.3 Market analysis by country

CHAPTER 6: INTERVENTIONAL ONCOLOGY MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Ambulatory Surgery Centers
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Research and Academic Institutes
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: INTERVENTIONAL ONCOLOGY MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Product Type
    • 7.2.3 North America Market size and forecast, by Cancer Type
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Product Type
      • 7.2.5.1.2 Market size and forecast, by Cancer Type
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Product Type
      • 7.2.5.2.2 Market size and forecast, by Cancer Type
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Product Type
      • 7.2.5.3.2 Market size and forecast, by Cancer Type
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Product Type
    • 7.3.3 Europe Market size and forecast, by Cancer Type
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Product Type
      • 7.3.5.1.2 Market size and forecast, by Cancer Type
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 U.K.
      • 7.3.5.2.1 Market size and forecast, by Product Type
      • 7.3.5.2.2 Market size and forecast, by Cancer Type
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 France
      • 7.3.5.3.1 Market size and forecast, by Product Type
      • 7.3.5.3.2 Market size and forecast, by Cancer Type
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Spain
      • 7.3.5.4.1 Market size and forecast, by Product Type
      • 7.3.5.4.2 Market size and forecast, by Cancer Type
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Italy
      • 7.3.5.5.1 Market size and forecast, by Product Type
      • 7.3.5.5.2 Market size and forecast, by Cancer Type
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Product Type
      • 7.3.5.6.2 Market size and forecast, by Cancer Type
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Product Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Cancer Type
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 China
      • 7.4.5.1.1 Market size and forecast, by Product Type
      • 7.4.5.1.2 Market size and forecast, by Cancer Type
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 Japan
      • 7.4.5.2.1 Market size and forecast, by Product Type
      • 7.4.5.2.2 Market size and forecast, by Cancer Type
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Product Type
      • 7.4.5.3.2 Market size and forecast, by Cancer Type
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 South Korea
      • 7.4.5.4.1 Market size and forecast, by Product Type
      • 7.4.5.4.2 Market size and forecast, by Cancer Type
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 Australia
      • 7.4.5.5.1 Market size and forecast, by Product Type
      • 7.4.5.5.2 Market size and forecast, by Cancer Type
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest Of Asia Pacific
      • 7.4.5.6.1 Market size and forecast, by Product Type
      • 7.4.5.6.2 Market size and forecast, by Cancer Type
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Product Type
    • 7.5.3 LAMEA Market size and forecast, by Cancer Type
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Product Type
      • 7.5.5.1.2 Market size and forecast, by Cancer Type
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Product Type
      • 7.5.5.2.2 Market size and forecast, by Cancer Type
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Product Type
      • 7.5.5.3.2 Market size and forecast, by Cancer Type
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Product Type
      • 7.5.5.4.2 Market size and forecast, by Cancer Type
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Medtronic, Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Boston Scientific Corporation
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 BD
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Terumo Corporation
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Merit Medical
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 AngioDynamics
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Johnson & Johnson
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Teleflex Incorporated
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Cook Group
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 HealthTronics, Inc.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments